Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | PTPRC | P08575 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL958187 | 0.80 | LMNA (0.46) | LMNAMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL3769766 | 0.78 | MEN1 (0.55) | LMNAMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL28304170 | 0.74 | LMNA (0.46) | LMNAMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL29752528 | 0.74 | LMNA (0.46) | LMNAMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL4832141 | 0.74 | MEN1 (0.41) | LMNAMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL4832146 | 0.74 | MEN1 (0.41) | LMNAMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL9207977 | 0.74 | GPR84 (0.42) | LMNAMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL9207972 | 0.74 | GPR84 (0.42) | LMNAMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL2797818 | 0.74 | MEN1 (0.45) | LMNAMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL5921807 | 0.73 | LMNA (0.50) | LMNAMAPTMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1811999-B1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2010-09-15 | — | — | EP | claimed |
| US-20100168132-A1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | PRESS NEIL JOHN | 2010-07-01 | — | — | US | claimed |
| US-20090048281-A1 | (R)-3-(2-Cyclohexyl-2-hydroxy-2-phenyl-acetoxy)-1-(isoxazol-3-ylcarbamoylmethyl)-1-azonia-bicyclo[2.2.2] octane, useful for treating inflammatory or obstructive airways diseases | NOVARTIS AG (CH) | 2009-02-19 | — | — | US | claimed |
| EP-1811999-A1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2007-08-01 | — | — | EP | claimed |
| WO-2006048225-A1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2006-05-11 | — | — | WO | claimed |
| US-8084463-B2 | Quinuclidine derivatives and their use as muscarinic M3 receptor antagonists | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| EP-1811999-B1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| EP-2206499-A1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| US-20100168132-A1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | PRESS NEIL JOHN | 2010-07-01 | — | — | US | disclosed |
| US-7723356-B2 | Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists | NOVARTIS AG (CH) | 2010-05-25 | — | — | US | disclosed |
| US-20090048281-A1 | (R)-3-(2-Cyclohexyl-2-hydroxy-2-phenyl-acetoxy)-1-(isoxazol-3-ylcarbamoylmethyl)-1-azonia-bicyclo[2.2.2] octane, useful for treating inflammatory or obstructive airways diseases | NOVARTIS AG (CH) | 2009-02-19 | — | — | US | disclosed |
| EP-1811999-A1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006048225-A1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048281-A1 | (R)-3-(2-Cyclohexyl-2-hydroxy-2-phenyl-acetoxy)-1-(isoxazol-3-ylcarbamoylmethyl)-1-azonia-bicyclo[2.2.2] octane, useful for treating inflammatory or obstructive airways diseases | CHRM3, CHRM2, CHRM1 | LMNA 3536/4885MAPT 3789/4885MEN1 4480/4885 |
| US-20100168132-A1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM1 | LMNA 3301/4885MAPT 2922/4885MEN1 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.